全文获取类型
收费全文 | 8274篇 |
免费 | 451篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 110篇 |
妇产科学 | 87篇 |
基础医学 | 1151篇 |
口腔科学 | 197篇 |
临床医学 | 487篇 |
内科学 | 2096篇 |
皮肤病学 | 85篇 |
神经病学 | 640篇 |
特种医学 | 387篇 |
外科学 | 1023篇 |
综合类 | 37篇 |
预防医学 | 255篇 |
眼科学 | 269篇 |
药学 | 724篇 |
中国医学 | 17篇 |
肿瘤学 | 1112篇 |
出版年
2023年 | 36篇 |
2022年 | 80篇 |
2021年 | 144篇 |
2020年 | 72篇 |
2019年 | 76篇 |
2018年 | 114篇 |
2017年 | 86篇 |
2016年 | 127篇 |
2015年 | 141篇 |
2014年 | 186篇 |
2013年 | 240篇 |
2012年 | 377篇 |
2011年 | 421篇 |
2010年 | 240篇 |
2009年 | 197篇 |
2008年 | 411篇 |
2007年 | 435篇 |
2006年 | 428篇 |
2005年 | 417篇 |
2004年 | 439篇 |
2003年 | 421篇 |
2002年 | 427篇 |
2001年 | 273篇 |
2000年 | 288篇 |
1999年 | 284篇 |
1998年 | 140篇 |
1997年 | 122篇 |
1996年 | 115篇 |
1995年 | 95篇 |
1994年 | 87篇 |
1993年 | 79篇 |
1992年 | 161篇 |
1991年 | 204篇 |
1990年 | 181篇 |
1989年 | 170篇 |
1988年 | 164篇 |
1987年 | 135篇 |
1986年 | 139篇 |
1985年 | 106篇 |
1984年 | 85篇 |
1983年 | 57篇 |
1982年 | 49篇 |
1981年 | 35篇 |
1980年 | 23篇 |
1979年 | 55篇 |
1978年 | 47篇 |
1977年 | 37篇 |
1976年 | 27篇 |
1975年 | 13篇 |
1966年 | 8篇 |
排序方式: 共有8766条查询结果,搜索用时 15 毫秒
1.
2.
3.
Kiyotaka YOH Makoto TAHARA Kenji KAWADA Hirofumi MUKAI Masanobu NAKATA Kuniaki ITOH Mitsuhiko KAWASHIMA Hideki NISHIMURA Ryuichi HAYASHI Takashi OGINO Hironobu MINAMI 《Asia-Pacific Journal of Clinical Oncology》2006,2(4):180-184
Background: Olfactory neuroblastoma is a rare sino‐nasal tumor arising from the olfactory epithelium and is often characterized by local invasion or metastasis. The role of chemotherapy in the treatment of this tumor is unclear. The purpose of this study was to review our institution’s experience of chemotherapy for advanced or recurrent olfactory neuroblastoma. Methods: Twenty‐one patients with histologically proven olfactory neuroblastoma were treated at our institution between 1992 and 2002. Twelve of these patients received chemotherapy in the setting of unresectable or recurrent disease and were retrospectively reviewed for clinical characteristics, treatment outcome or survival. Results: Eight patients of the 12 patients received cisplatin‐based chemotherapy and the remaining four patients received chemotherapy consisting of docetaxel plus irinotecan (three patients) or cyclophosphamide, doxorubicin, and vincristine (1 patient). A partial response was achieved in five patients, with an overall response rate of 42%, although the chemotherapeutic regimens were heterogeneous. Two partial responses were obtained among the three patients who received docetaxel plus irinotecan. The response rate to chemotherapy was 83% in the younger age group (<40 years), as opposed to 0% in the older age group (≥40 years), and the difference between the two groups was statistically significant (P = 0.02). Conclusion: Our study indicated that olfactory neuroblastoma would be sensitive to chemotherapy, especially with young patients. Docetaxel plus irinotecan has the possibility of showing favorable response, and warrants further investigation. 相似文献
4.
5.
Shiro Akinaga Tadashi Ashizawa Katsushige Gomi Hiroe Ohno Makoto Morimoto Chikara Murakata Masami Okabe 《Cancer chemotherapy and pharmacology》1992,29(4):266-272
Summary Novel derivatives of K-252a, (8R*,9S*,11S*)-(–)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8, 11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo [a,g]-cycloocta[cde]trinden-1-one, an inhibitor of protein kinases and calmodulin-dependent phosphodiesterase, were synthesized and evaluated for their antitumor activity in vitro and in vivo. Of ten derivatives tested, four were active against the P388 murine leukemia i. p.-i. p. system, although K-252a was inactive. Among these derivatives, KT6124 was selected for further biological evaluation studies because its efficacy was the highest. KT6124 was also active against sarcoma 180 and B16 melanoma. It exerted a relatively broad spectrum of antiproliferative activity against 20 human tumor cell lines in vitro. To determine the mechanism(s) of action underlying the antitumor activity of KT6124, we tested the drug for inhibition of protein kinases, including Ca2+-and phospholipid-dependent protein kinase (PKC), in intact A431 human epidermoid carcinoma cells in comparison with the PKC-inhibitory activity of K-252a. KT6124 did not antagonize the action of phorbol 12-myristate 13-acetate (PMA) in A431 cells, whereas K-252a did, suggesting that KT6124 may not act on protein kinases in the cells. The interaction of KT6124 with DNA in living cells was examined by the alkaline elution method. KT6124 apparantly exhibited DNA scission both dose-and time-dependently in the target cells. The DNA breakage was dependent on proteinase K treatment, suggesting its possible interaction with DNA-related enzyme(s). These results indicate that KT6124 exerts antitumor activity by acting on DNA or on DNA-related enzyme(s) in tumor cells rather than via the inhibition of protein kinases. 相似文献
6.
Previous studies have demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) both increases and decreases levels of 3'-azido-3'-deoxythymidine (AZT) nucleotides in certain human myeloid cells. The present studies have examined the effects of GM-CSF on AZT metabolism in U-937 cells. The results demonstrate that GM-CSF stimulated AZT nucleotide formation in these cells. This stimulation was detectable during concurrent exposure to GM-CSF and AZT or as a result of pretreatment with GM-CSF. The GM-CSF-induced enhancement in AZT nucleotide formation was associated with a 4-fold increase in AZT uptake. The finding that uptake of AZT into U-937 cells was only partially sensitive to 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine (NBMPR) suggested a process primarily involving nonfacilitated diffusion. The results also demonstrate that treatment of U-937 cells with GM-CSF was associated with nearly a 2-fold increase in thymidine kinase activity. Moreover, the findings indicate that retention of AZT-MP and AZP-TP was prolonged significantly (P less than 0.05 and P less than 0.01 respectively) in association with GM-CSF treatment. Taken together, these results suggest that GM-CSF enhances the formation of AZT nucleotides by increasing AZT uptake and phosphorylation, as well as increasing retention of phosphorylated derivatives. 相似文献
7.
Yoshiro Matsui Mizuho Ohta Kohsuke Ohno Masao Nagumo 《Journal of oral and maxillofacial surgery》2006,64(10):1540-1545
PURPOSE: This study evaluated the bone volume, height, and width that can be obtained in alveolar ridge augmentation using titanium mesh and autogenous bone particles in patients with cleft lip/palate. PATIENTS AND METHODS: Subjects were 15 patients with cleft lip/palate requiring tertiary bone graft for implant therapy. Computed tomography (CT) scans were taken before removing the mesh, from 1 to 21 months after bone grafting. Forty-three reconstructed images corresponding to the positions for implant placement were selected for this study. The percent defect filled with bone (%BONE), defined as the percentage of newly formed bone in the space created by the mesh, was measured for image analyses. In linear analyses, 4 parameters were used: increased bone height (IBH), percent increased bone height (%IBH), increased bone width (IBW), and percent increased bone width (%IBW). Factors influencing the quantitative data and the clinical courses of placed implants were also explored. RESULTS: The average %BONE was 91.1%. IBH averaged 4.4 mm, whereas %IBH averaged 88.5%. IBW averaged 4.6 mm, whereas %IBW averaged 86.4%. Little correlation was present between the quantitative data and patient age, or time interval. A significant correlation was identified between the data for span of the grafted area and %BONE (correlation coefficient value = -0.36). However, the diminishing rate was very low. No implants were lost postoperatively. CONCLUSIONS: Alveolar ridge augmentation with titanium mesh and autogenous bone particles from the anterior iliac crest has very high predictability as a preimplant procedure in patients with cleft lip/palate. 相似文献
8.
9.
Ryo Wakita Yuka Ohno Saori Yamazaki Hikaru Kohase Masahiro Umino 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2006,102(6):e28-e32
Two cases of vasovagal syncope (VVS) during venous access are reported. Both patients had a history of fainting episodes and experienced bradycardia with asystole, hypotension, and fainting. Pain and phobic stress during venous access triggered an increase in parasympathetic tone, resulting in bradycardia with asystole and hypotension in both cases. Hypotension and bradycardia likely caused cerebral hypoperfusion, leading to fainting. The intense parasympathetic tone triggered by somatic or emotional stress was likely responsible for directly depressing the sinus node, leading to asystole and bradycardia. Bradycardia with asystole progressing to syncope is a potentially fatal dysrhythmia in patients with cardiovascular disease or older patients with decreased cardiac function. Appropriate treatment for VVS includes the administration of intravenous fluids, vagolytics, ephedrine, and the rapid use of the Trendelenburg position. Intravenous fluids and atropine were used to treat the present patients. 相似文献